Ki -67 proliferative index as a predictive tool for axillary pathological complete response in node-positive breast cancer

International Journal of Medical Science
© 2020 by SSRG - IJMS Journal
Volume 7 Issue 11
Year of Publication : 2020
Authors : Abdalla Saad Abdalla Al-Zawi
How to Cite?

Abdalla Saad Abdalla Al-Zawi, "Ki -67 proliferative index as a predictive tool for axillary pathological complete response in node-positive breast cancer," SSRG International Journal of Medical Science, vol. 7,  no. 11, pp. 1-4, 2020. Crossref,


Background: Upfront chemotherapy is considered the standard of care in the management of early breast cancer including node-positive disease.Ki-67 proliferation index is a biomarker that can be used to predict the histopathological response to therapeutic upfront chemotherapy in the breast primary tumor as well as predict the prognosis.
Objective: Our aim in this study, to address the predictive/prognostic value of Ki-67 proliferative index in downgrading the axilla in node-positive breast cancer. Material and Methods: A group of 64 patients included, have been diagnosed with node-positive breast cancer and triaged for neoadjuvant chemotherapy before surgical intervention. The Ki-67 proliferative index has been measured before chemotherapy and the correlation between Ki-67 expression and achievement of pathological complete response has been explored.
Results: The patient's group with high Ki-67 and both breast and axillary p-CR is 08 patients (12.5%), and the group with high Ki-67 and only axillary p-CR is 07 patients (11%), which gives a sum of 15 patients (23.4%) who achieved p-CR.
Conclusion: The outcome of the current study shows that there was a marginally significant correlation between the p-CR (Complete Pathological Response) and higher rates of Ki-67 expression.


Breast cancer, Ki-67, Neoadjuvant chemotherapy, Axillary lymph nodes


[1] Asaad, A., et al., "Breast Metastasis as a Presentation of Malignant Melanoma". Chirurgia (Bucur), 2018. 113(5): p. 712-718.
[2] Kim, K.I., et al., "Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients". Journal of breast cancer, 2014. 17(1): p. 40-46.
[3] Moazed, V., et al., "Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014". Iranian Journal of pathology, 2018. 13(1): p. 71-77.
[4] Saad Abdalla Al-Zawi, A., et al., "Metastatic Breast Cancer to the Cervix Presenting with Abnormal Vaginal Bleeding During Chemotherapy: A Case Report and Literature Review". Chirurgia (Bucur), 2018. 113(4): p. 564-570.
[5] Soliman, N.A. and S.M. Yussif, "Ki-67 as a prognostic marker according to breast cancer molecular subtype". Cancer Biol Med, 2016. 13(4): p. 496-504.
[6] Gerdes, J., et al., "Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation". International Journal of Cancer, 1983. 31(1): p. 13-20.
[7] Inwald, E.C., et al., "Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry". Breast Cancer Research and Treatment, 2013. 139(2): p. 539-552.
[8] Saad Abdalla Al-Zawi, A. and A. Syed, "Ki67 Proliferation index as a prognostic and predictive tool for a pathological response after upfront chemotherapy in breast cancer". Paripex Indian Journal of Research, 2020. 9(11).
[9] Varga, Z., et al., "Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort". Scientific Reports, 2019. 9(1): p. 13534.
[10] Kermani, T. and I. Kermani, "Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors". Biomedical Research and Therapy, 2019. 6(2): p. 6.
[11] Mariam Shadan, Nazoora Khan, Mohammad Amanullah Khan, Hena Ansari and Sufian Zaheer, "Histological categorization of stromal desmoplasia in breast cancer and its diagnostic and prognostic utility" SSRG International Journal of Medical Science 4.6 (2017): 8-11.
[12] Liu, Y., et al., [Prognostic significance of Ki-67 expression before and after neoadjuvant chemotherapy in different biological breast cancer phenotypes]. Zhonghua Zhong Liu Za Zhi, 2014. 36(9): p. 671-6.
[13] Petrelli, F., et al., "Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients". Breast Cancer Res Treat, 2015. 153(3): p. 477-91.
[14] de Azambuja, E., et al., "Ki-67 as a prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients". British journal of cancer, 2007. 96(10): p. 1504-1513.
[15] Tan, Q.-X., et al. "Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy". International journal of clinical and experimental pathology, 2014. 7, 6862-6870.
[16] Molino, A., et al., "Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis". Int J Cancer, 1997. 74(4): p. 433-7.
[17] Boughey, J.C., et al., "Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial". JAMA, 2013. 310(14): p. 1455-1461.
[18] Kuehn, T., et al., "Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study". The Lancet Oncology, 2013. 14(7): p. 609-618.